Navigation Links
Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:9/4/2012

PHILADELPHIA, Sept. 4, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics, will present at the Rodman & Renshaw Annual Global Investment Conference.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

Dr. Mooney will make a corporate presentation to prospective corporate partners and investors at 3:15 PM ET on Tuesday, September 11th in New York City.  

At the time of the presentation, a live audio webcast, with slides, of Dr. Mooney's presentation will be available on the company's website at www.echotx.com.  The webcast will then be available for 90 days following the event.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio                                                          
Director, Investor Relations and Corporate Communications
colimpio@echotx.com
(215) 717-4104                                                                   

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
2. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
3. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
4. Global Markets for Animal Therapeutics and Diagnostics
5. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
6. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
7. Aethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract
8. Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
9. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
10. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
11. Nile Therapeutics Reports 2012 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... May 23, 2016 Global Paclitaxel ... pages, profiles 12 companies and the Paclitaxel analysis in ... on the industry and its players. This ... in nature, details the current state of the industry ... definitions, classifications, applications and industry chain structure. The Paclitaxel ...
(Date:5/23/2016)... 2016 Clarifying Vision - Prospects ... and Vision Care What can be expected ... to grow at the fastest rates? This visiongain ... data, trends, opportunities and prospects. ,Our ... the most lucrative areas in the industry and the ...
(Date:5/23/2016)... May 23, 2016 Gamida Cell, ... treatment of cancer and orphan genetic diseases, announced today ... $4.4 million from the Israel Innovation Authority (formerly the ... of Economy and Industry. The mission of the Israel ... various industries, including science and technology, while stimulating economic ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... ... The University of San Francisco (USF) has named Margaret Wooding Baker dean ... more than 100 full-time faculty and staff, and serve as a member of the ... Baker comes to USF from the University of Washington in Seattle, where she is ...
(Date:5/25/2016)... FLA (PRWEB) , ... May 25, 2016 , ... ... technology to help turn back the hands of time of female aging. The ... and childbirth. Women with symptoms such as leakage, laxity, itchiness and pain have ...
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State ... Meeting for their work on visual evoked potential and human attention. The article, ... used the Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... builder, has announced that it will join America's leading engineers at the American ... held at the Georgia World Congress Center. , Engineers, speakers and exhibitors ...
(Date:5/24/2016)... ... May 24, 2016 , ... According to an article ... people randomly assigned to reduce the amount of calories they consumed by 25% experienced ... body weight enjoyed better sleep, improved quality of life, and enhanced sexual function compared ...
Breaking Medicine News(10 mins):